Citius Pharmaceuticals (NASDAQ:CTXR) Announces Quarterly Earnings Results

by · The Cerbat Gem

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) released its earnings results on Friday. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of $0.39 by ($1.34), FiscalAI reports.

Citius Pharmaceuticals Stock Performance

CTXR traded down $0.02 on Friday, reaching $0.70. The company’s stock had a trading volume of 516,793 shares, compared to its average volume of 1,069,212. The stock has a 50 day moving average of $0.79 and a two-hundred day moving average of $0.92. Citius Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.48.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTXR. XTX Topco Ltd acquired a new position in Citius Pharmaceuticals in the second quarter valued at approximately $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the second quarter valued at approximately $40,000. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals in the fourth quarter valued at approximately $46,000. Finally, Heights Capital Management Inc. acquired a new position in Citius Pharmaceuticals in the fourth quarter valued at approximately $622,000. 16.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on CTXR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. D. Boral Capital reissued a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.00.

Check Out Our Latest Report on Citius Pharmaceuticals

Citius Pharmaceuticals Company Profile

(Get Free Report)

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.

See Also